spacer
home > ict > spring 2008 > more than a sleeping partner
PUBLICATIONS
International Clinical Trials

More Than a Sleeping Partner

Martin King of LCG Bioscience outlines some of the most common sleep disorders and their implications, and explains the techniques available for practitioners undertaking specialist sleep trials

Sleep medicine is a fairly new speciality, having been only properly developed within the last 20 years or so. There are currently 89 sleep disorders on the list of International Classification of Sleep Disorders and this is growing all the time (1). The disorders are divided into three groups: dyssomnias, which can be insomnia or hypersomnia (where people sleep too much); parasomnias, which describe undesired events that occur alongside sleep; and medical and psychiatric disorders that affect sleep.

The main area of interest for new sleep drug development by the pharmaceutical industry is the dyssomnia group. It is estimated that 30-35 per cent of the population suffer from some form of insomnia at any time and the economic consequences are dramatic. Insomniacs seem to have more frequent visits to their doctor for other complaints, they probably suffer low mood, and they lose more days from work. So, in terms of the cost to the nation, insomnia is important.

THE MARKET FOR SLEEP MEDICATION

The low number of prescribed hypnotics and the high number of over-the-counter sleep aids indicate that there is the potential for massive growth in sales of new hypnotics. Pharmaceutical companies have produced and, continue to develop, hypnotics and treatments for insomnia, and alerting medications to combat sleepiness, particularly daytime sleepiness.

However, there are different types of insomnia. Take, for example, transient insomnia. We are all aware that anxiety can bring on insomnia – perhaps if you are worried about the events of the next day. Or you may have insomnia because you’ve drunk too much coffee.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Martin King began his career in sleep medicine around 20 years ago, and has worked in the NHS and the private sector, and has spent a brief period in the US. He is a member of the World Association of Sleep Medicine, the European Sleep Research Society, American Academy of Sleep Medicine and the British Sleep Society. Martin was Manager of the UK’s largest clinical sleep laboratory and he has assessed thousands of patients across the spectrum of sleep disorders. He has authored papers in a number of peer reviewed journals and is regularly asked to contribute to teaching programmes. Martin recently joined LCG Bioscience in Cambridge, UK, to head the new sleep facility which is designed to deliver both early and late phase clinical trials
spacer
Martin King
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement